Affordable Access

Access to the full text

Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review

Authors
  • Rezk, Mourad F.1
  • Pieper, Burkhard1
  • 1 Biogen International GmbH, Neuhofstrasse 30, Baar, 6340, Switzerland , Baar (Switzerland)
Type
Published Article
Journal
Advances in Therapy
Publisher
Springer Healthcare
Publication Date
Aug 01, 2020
Volume
37
Issue
9
Pages
3732–3745
Identifiers
DOI: 10.1007/s12325-020-01437-4
Source
Springer Nature
Keywords
License
Green

Abstract

Immune-mediated inflammatory diseases (IMIDs) are chronic conditions that create a significant disease burden on millions of patients while adding a major financial burden to societies and healthcare systems. The introduction of biologic medicines has contributed majorly to improving the clinical outcomes of IMIDs and as such these modalities have gained first- or second-line positions in a wide range of treatment guidelines from different international clinical societies. However, the high cost of these biologics traditionally limited their accessibility and delayed their initiation, leaving millions of patients with unmet medical needs for a more affordable and sustainable solution. The introduction of cost-efficient biosimilar anti-TNFs within Europe since 2013 has allowed more patients with IMIDs to access biologic therapies earlier and for longer, potentially altering the course of the disease into a milder phenotype and reducing the long-term disease burden. This review provides the latest evidence for the impact of biosimilars on patient outcomes and demonstrates their clinical value beyond a reduction in price.

Report this publication

Statistics

Seen <100 times